Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC
News
The Canadian Cancer Trials Group (CCTG) has launched a Phase 2 study of CFI-400945 in combination with Imfinzi (durvalumab) for the treatment of advanced or metastatic triple negative breast cancer (TNBC). ... Read more